Standard-Dose Trifluridine/Tipiracil as Safe Treatment Alternative in Metastatic Colorectal Cancer Patients With DPD Deficiency
- 14 September 2021
- journal article
- editorial
- Published by Elsevier BV in Clinical Colorectal Cancer
- Vol. 20 (4), 359-363
- https://doi.org/10.1016/j.clcc.2021.09.004
Abstract
No abstract availableKeywords
This publication has 11 references indexed in Scilit:
- Fluoropyrimidines and DPD testing: is there truly an inexorable link?European Journal of Cancer, 2019
- DPYD genotype-guided dose individualisation of fluoropyrimidine therapy in patients with cancer: a prospective safety analysisThe Lancet Oncology, 2018
- Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Dihydropyrimidine Dehydrogenase Genotype and Fluoropyrimidine Dosing: 2017 UpdateClinical Pharmacology & Therapeutics, 2017
- Trifluridine/Tipiracil: A Review in Metastatic Colorectal CancerDrugs, 2016
- Improving safety of fluoropyrimidine chemotherapy by individualizing treatment based on dihydropyrimidine dehydrogenase activity – Ready for clinical practice?Cancer Treatment Reviews, 2016
- Upfront Genotyping of DPYD*2A to Individualize Fluoropyrimidine Therapy: A Safety and Cost AnalysisJournal of Clinical Oncology, 2016
- TAS-102, a novel antitumor agent: A review of the mechanism of actionCancer Treatment Reviews, 2015
- Clinical relevance of DPYD variants c.1679T>G, c.1236G>A/HapB3, and c.1601G>A as predictors of severe fluoropyrimidine-associated toxicity: a systematic review and meta-analysis of individual patient dataThe Lancet Oncology, 2015
- Translating DPYD genotype into DPD phenotype: using the DPYD gene activity scorePharmacogenomics, 2015
- Randomized Trial of TAS-102 for Refractory Metastatic Colorectal CancerThe New England Journal of Medicine, 2015